Patents by Inventor Joerg Kaufmann
Joerg Kaufmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240133714Abstract: A device for determining an encoder magnet rotation angle is provided, wherein the device includes an encoder magnet and a number of n greater than or equal to two magnet sensors. The magnetic field includes a plurality of plane-parallel magnetic field planes, wherein a surface normal of the plane-parallel magnetic field planes is parallel to an encoder magnet rotation axis. The magnetic field further includes a plurality of magnetic field vectors in the plane-parallel magnetic field planes. The two magnet sensors are in at least one of the plane-parallel magnetic field planes, wherein a first magnetic field vector has a first angle at a position of a first magnet sensor, and wherein a number n?1 of further ones of the magnet sensors are arranged at positions in the magnetic field whose magnetic field vectors have an angle which satisfies the equation ? i = ? i - 1 + 360 ? ° n , wherein 1<i?n.Type: ApplicationFiled: October 5, 2023Publication date: April 25, 2024Inventors: Jörg Franke, Timo Kaufmann, Johannes Gutmann
-
Patent number: 11796540Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.Type: GrantFiled: July 26, 2019Date of Patent: October 24, 2023Assignee: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
-
Publication number: 20230295651Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?-> 3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3? UTR, wherein the 5? UTR is selected from the group consisting of a 5? UTR of a gene coding for MCP-1 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for RPL12s.c. or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for Ang-2 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for H3.3.Type: ApplicationFiled: August 10, 2022Publication date: September 21, 2023Inventors: Joerg KAUFMANN, Oliver KEIL, Daniel TONDERA
-
Publication number: 20230263819Abstract: The present invention is related to a composition comprising a lipid composition, a tricarboxylic acid and a nucleic acid molecule, wherein the lipid composition comprises a cationic lipid, a neutral lipid and a shielding lipid, wherein a positive charge excess arising from a larger number of positive charges provided by the cationic lipid molecules in the composition compared to the smaller number of negative charges provided by the nucleic acid molecules in the composition is compensated by the charges provided by the tricarboxylic acid; and methods of use of such composition.Type: ApplicationFiled: August 10, 2022Publication date: August 24, 2023Inventors: Volker FEHRING, Jörg KAUFMANN, Oliver KEIL, Daniel TONDERA
-
Patent number: 11715309Abstract: A method for producing security elements in an image which are not visible to the human eye and which cannot be copied, in particular for checking the authenticity of images. The image is imaged by means of a halftone, the halftone consisting of individual image dots arranged adjacent to each other. This is characterized in that at least one field having a random geometric shape or freeform is defined in the image/the halftone. By means of manipulation of image dots in the field and/or by means of manipulation of the entire field, an encrypted information that cannot be copied is stored for comparison with at least one database and the serial number is displayed by means of contours formed in the halftone.Type: GrantFiled: June 22, 2019Date of Patent: August 1, 2023Assignee: authentic.network GmbHInventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
-
Patent number: 11587339Abstract: A method for checking the authenticity of products, by checking an image (A) of a product. The proof of authenticity is not visible to the human eye and cannot be copied. This is characterized in that a code stored in a halftone image by manipulation of dots and/or a manipulated field bounded in the halftone image can be read by means of an optical device and compared with a retrievable value in at least one database. In at least one field (F1 to F5) a part of a serial number is determined which describes the structure of the serial number and a hash function used for transmitting the serial number to the database, and this is also characterized in that the serial number is subsequently assembled and encrypted with the corresponding hash function.Type: GrantFiled: June 22, 2019Date of Patent: February 21, 2023Assignee: Industry 365 UG (Haftungsbeschränkt)Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
-
Patent number: 11578328Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: August 7, 2020Date of Patent: February 14, 2023Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 11532845Abstract: A battery cell in the form of a round cell, having: at least one electrode element having an inner side and an outer side and at least one temperature control element, wherein the inner side of the at least one electrode element is spaced apart, at least in sections, from the outer side of the at least one electrode element by means of the temperature control element.Type: GrantFiled: November 4, 2019Date of Patent: December 20, 2022Assignee: VOLKSWAGEN AKTIENGESELLSCHAFTInventors: Volker Hohm, Bastian Schaar, Frank Wesche, Joerg Kaufmann, Helge Herten
-
Publication number: 20210261980Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?->3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3?UTR, wherein the 5? UTR is selected from the group comprising a 5? UTR of a gene or a derivative thereof having a nucleotide identity of at least 85%, wherein the gene is selected from the group consisting of MCP-1, RPL12s.c., Ang-2, HSP70, H3.3., Galectin-9, GADD34, EDN1, HSP70m5, E-selectin, ICAM-1, IL-6 and vWF.Type: ApplicationFiled: February 10, 2021Publication date: August 26, 2021Inventors: Klaus GIESE, Oliver KEIL, Jörg KAUFMANN
-
Publication number: 20210245542Abstract: A method for producing security elements in an image which are not visible to the human eye and which cannot be copied, in particular for checking the authenticity of images. The image is imaged by means of a halftone, the halftone consisting of individual image dots arranged adjacent to each other. This is characterized in that at least one field having a random geometric shape or freeform is defined in the image/the halftone. By means of manipulation of image dots in the field and/or by means of manipulation of the entire field, an encrypted information that cannot be copied is stored for comparison with at least one database and the serial number is displayed by means of contours formed in the halftone.Type: ApplicationFiled: June 22, 2019Publication date: August 12, 2021Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
-
Publication number: 20210248369Abstract: A method for checking the authenticity of products, by checking an image (A) of a product. The proof of authenticity is not visible to the human eye and cannot be copied. This is characterized in that a code stored in a halftone image by manipulation of dots and/or a manipulated field bounded in the halftone image can be read by means of an optical device and compared with a retrievable value in at least one database. In at least one field (F1 to F5) a part of a serial number is determined which describes the structure of the serial number and a hash function used for transmitting the serial number to the database, and this is also characterized in that the serial number is subsequently assembled and encrypted with the corresponding hash function.Type: ApplicationFiled: June 22, 2019Publication date: August 12, 2021Inventors: Jörg Kaufmann, Frank Theeg, Holger Zellmer
-
Publication number: 20210062198Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: August 7, 2020Publication date: March 4, 2021Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Patent number: 10774332Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: May 3, 2019Date of Patent: September 15, 2020Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20200144685Abstract: A battery cell in the form of a round cell, having: at least one electrode element having an inner side and an outer side and at least one temperature control element, wherein the inner side of the at least one electrode element is spaced apart, at least in sections, from the outer side of the at least one electrode element by means of the temperature control element.Type: ApplicationFiled: November 4, 2019Publication date: May 7, 2020Applicant: Volkswagen AktiengesellschaftInventors: Volker Hohm, Bastian Schaar, Frank Wesche, Joerg Kaufmann, Helge Herten
-
Publication number: 20190390201Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second grand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: May 3, 2019Publication date: December 26, 2019Applicant: Silence Therapeutics GMBHInventors: Klaus GIESE, Jörg KAUFMANN, Anke KLIPPEL-GIESE
-
Publication number: 20190346439Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.Type: ApplicationFiled: July 26, 2019Publication date: November 14, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
-
Patent number: 10329568Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: September 5, 2018Date of Patent: June 25, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 10323246Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: August 15, 2017Date of Patent: June 18, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 10266829Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: June 20, 2018Date of Patent: April 23, 2019Assignee: Silence Therapeutics GMBHInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20190038557Abstract: The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (I) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, Y? is an anion, wherein each of R1 and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II) wherein each of R3 and R4 is individually and independently linear C13-C17 alkyl, and p is any integer from 15 to 130; a PEGylated ceramide of formula (III) wherein R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV) wherein each of R6 and R7 is individuallyType: ApplicationFiled: February 14, 2018Publication date: February 7, 2019Inventors: Oliver KEIL, Jörg KAUFMANN, Volker FEHRING, Ute SCHAEPER